07:00 , Mar 30, 2009 |  BC Week In Review  |  Company News

Abeille, ProStrakan deal

ProStrakan received exclusive, worldwide rights excluding certain Asian territories to develop, commercialize and sub-license Abeille's AB-1001. The transdermal granisetron patch has completed Phase I trials to treat chemotherapy-induced nausea and vomiting (CINV). ProStrakan...
07:00 , Aug 4, 2008 |  BC Week In Review  |  Clinical News

SyB D-0701: Phase I completed

SymBio completed a pair of Japanese Phase I trials. The company has exclusive rights to SyB D-0701 in Japan and other East Asian countries from Abeille, which is developing it as AB-1001. Abeille Pharmaceuticals Inc.,...
08:00 , Jan 8, 2007 |  BioCentury  |  Finance

Late stage milestones

Late stage milestones Company name Product name Indication Event Milestone Abeille AB-1001 Emesis Submit NDA 3Q07 Acambis (LSE:ACM; ACAM) ChimeriVax-JE vaccine Japanese encephalitis Final Ph III data 1Q07 ActivBiotics Rifalazil Peripheral vascular...
07:00 , Aug 14, 2006 |  BC Week In Review  |  Clinical News

AB-1001: Phase III start

Abeille will begin a double-blind, international Phase III study in an undisclosed number patients by year end. Abeille Pharmaceuticals Inc., Princeton, N.J.   Product: AB-1001   Business: Gastrointestinal   Molecular target: Serotonin (5-HT3) receptor   Description: Transdermal...
07:00 , May 8, 2006 |  BC Week In Review  |  Company News

Abeille, NexMed deal

NEXM granted Abeille an exclusive worldwide license to use NexACT delivery technology for transdermal patch applications. Further terms were not disclosed. Abeille Pharmaceuticals Inc., Princeton, N.J.   NexMed Inc. (NEXM), East Windsor, N.J.   Business: Drug delivery...
08:00 , Feb 6, 2006 |  BC Week In Review  |  Clinical News

AB-1001: Phase I start

Abeille started an open-label, 3-month, 3-way crossover, U.S. Phase I trial in 12 healthy volunteers to compare 2 doses of AB-1001 patch with IV administration of the product. Abeille Pharmaceuticals Inc., Princeton, N.J.   Product: ...
08:00 , Nov 21, 2005 |  BC Week In Review  |  Company News

Abeille scientific advisory board update

Abeille Pharmaceuticals Inc., Princeton, N.J.   Business: Drug delivery   Appointed: John Babish, SVP of Ashni Naturaceuticals Inc.; Douglas Flanagan, professor of pharmaceutics at the University of Iowa; Om Ganda, associate clinical professor of medicine at...
07:00 , Jun 6, 2005 |  BC Week In Review  |  Company News

Abeille board of directors update

Abeille Pharmaceuticals Inc., Princeton, N.J.   Business: Drug delivery   Appointed: Zsolt Lavotha, president and CEO of Orexo AB; and James Warren, former CEO of Banner Pharmcaps Inc.   ...